FDA Advisory Panel Reviewed Multi-Cancer Screening Test
The Galleri screening tool, designed to detect cancer early, faces an upcoming FDA committee review.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Is now a good time to invest in medical companies developing early cancer detection technologies?
The Galleri multi-cancer screening tool is nearing a key regulatory milestone as an FDA advisory committee prepares to meet on September 23, 2026. This test aims to identify cancers that currently lack standard screening protocols by analyzing shared methylation patterns.
Why it matters
If approved, this diagnostic tool could shift cancer care toward earlier detection in individuals before physical symptoms appear. The potential market for this screening exceeds 100 million people in the United States alone.
The Galleri test was evaluated in the NHS-Galleri trial, which notably missed its primary clinical goal. Results of further investigations and the upcoming FDA advisory review are pending.
The players
Grail Inc.
A developer of multi-cancer early detection testing technology.
Epic
A major provider of electronic health record systems for healthcare organizations.
RBC Capital Markets
A financial institution that provides investment research and stock analysis.
The details
The Galleri tool works by identifying specific DNA methylation patterns that are shared across various types of cancer. Through a collaboration with Epic, the test results can be integrated into the electronic health records used by 450 health systems. This infrastructure is intended to streamline how clinicians access and interpret screening findings.
Timeline
April 2026: Grail announced a collaboration with Epic.
September 17, 2026: RBC Capital Markets initiated coverage on Grail Inc.
September 18, 2026: Grail shares traded at $80.12.
September 23, 2026: FDA advisory committee meeting for Galleri.
Late 2026/Early 2027: Potential FDA approval for the Galleri test.
Health Landscape
The upcoming FDA review follows the NHS-Galleri trial, which failed to meet its primary objective. This development marks a critical juncture in the broader evolution of blood-based cancer diagnostics.
If you are interested in screening options that fall outside standard clinical guidelines, consider discussing the current status of multi-cancer early detection with your primary care physician. It is important to wait for formal FDA guidance before drawing conclusions about the utility of these new tests.
The takeaway
Early detection research is shifting toward testing for biomarkers across multiple cancer types. Readers should continue to prioritize established, evidence-based screenings recommended by their doctor while monitoring regulatory developments for new technologies.
What happens next
The FDA advisory committee is scheduled to meet on September 23, 2026, to discuss the Galleri test, with potential regulatory approval anticipated between late 2026 and early 2027.
Further reading
For more on the current state of diagnostic screenings, visit the Cancer section.
Source note: This article includes information reported by Benzinga.
Live Poll
Is now a good time to invest in medical companies developing early cancer detection technologies?
